From Boardroom to Benchtop: Paul LaViolette Joins SVLS
This article was originally published in Start Up
Paul LaViolette spent more than a decade at Boston Scientific where, among other things, he helped build the company into a cardiovascular powerhouse. LaViolette announced his retirement from BSC last year and after considering a number of opportunities, decided to join Boston-based SVLS as a venture partner. LaViolette enters venture investing at a challenging time, during which the industry will face what he calls "a Darwinian process with more operational pressure" at start-ups and a likely weeding out of many companies. In this interview, LaViolette describes how the venture world of 2008 feels a lot like Boston Scientific in 1993 -- a world of small, driven companies with huge operational challenges and huge opportunities.
You may also be interested in...
Medical Device Investing: Financing in an Economic Crisis
At FDC-Windhover's October IN3 East conference, we asked a distinguished panel of experienced venture capitalists to share their insights on the downturn in medtech venture investing. We invited our panelists to weigh in on the role of the current crisis in the second and third quarter slowdown in device investing and what it would mean going forward for a sector that had been so frothy just a short time earlier.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign
Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.